UK Lung Cancer Consultants

Dr Kate Fife is a Consultant Clinical Oncologist based at Addenbrooke's Hospital in Cambridge. She was appointed in 2001.

Dr Fife trained in medicine at St George’s Hospital in London and went on to train in oncology at the Royal Marsden Hospital. She carried out clinical research in HIV related malignancies whilst a research fellow at Chelsea and Westminster, and Charing Cross Hospitals and completed an MD in angiogenesis related laboratory research in 1998. She completed her oncology training at the Hammersmith Hospital. Subsequently she was a locum Consultant and research fellow at the Sydney Cancer Centre and Sydney Melanoma Unit, carrying out further laboratory and clinical research.

Together with Prof Tim Eisen and Dr Athena Matakidou, she runs a large research focussed renal cancer clinic, seeing approximately 130 new patients per year, making it one of the largest specialist centres for this cancer in the UK.  Her other interests are skin malignancies and lung cancer. She treats basal cell and squamous cell cancers of the skin and metastatic melanoma with radiotherapy and patients with rare skin cancers, cutaneous lymphomas and Kaposi’s sarcoma. She is also interested in training and is an educational supervisor.

She is a member of the National Cancer Research Institute Renal Cancer Studies Group and has a frequent attendance and presentations at National and International meetings. 

Dr Jeremy Braybrooke is a Consultant Medical Oncologist at University Hospitals Bristol NHS Foundation trust.

Dr Baybrook completed his undergraduate training at Southampton University and in Medical Oncology at the Cancer Research UK Medical Oncology unit in Oxford. During this time he completed a PhD, supervised by Professor Adrian Harris and Professor Ian Hickson, studying DNA damage and repair. He was appointed to his current consultant post in Bristol in 2003 and has developed a large patient focused clinical practice and is passionate about clinical research and improving patients' experience of chemotherapy treatments. He is actively involved in fund-raising for 'Above and Beyond' and 'It's in the Bag' charities improving awareness of testicular cancer.

Dr Braybrooke has been a member of the NICE Lung Cancer Clinical Guideline Development Group and currently sits on a NICE Technology Appraisal Committee evaluating new medicines. He is also a member of the American Society of Clinical Oncology, and was a member of the National Cancer Research Network Testicular Cancer Clinical Studies Group (2005 - 2010) and was Chair of Avon Somerset and Wiltshire Cancer Network Breast Cancer Site Specific Group (until April 2010)

Dr Jason Lester is a Consultant Clinical Oncologist based at The Velindre Cancer Centre in Cardiff.

Dr Lester qualified from Guy's Hospital Medical School, London in 1993 and trained in general medicine in the South East of England. He completed his oncological training in 2003, and was appointed as a Consultant Oncologist at Velindre Cancer Centre the same year, where he is currently Deputy Clinical Director and Lead Clinican for lung cancer in the Trust, bringing vast experience and expertise and offering specialist cancer diagnosis and treatment.

He advises patients on all aspects of Non-surgical treatment of lung cancer, mesothelioma and urological cancers (prostate, kidney and bladder cancer); Chemotherapy and targeted therapy for lung and urological cancers; Stereotactic radiotherapy for early lung cancer; Combined modality therapy for locally advanced lung cancer; Brachytherapy for prostate cancer; IMRT / IGRT radiotherapy for prostate cancer; Bladder sparing treatment for bladder cancer. He is responsible for prescribing and supervising the administration of radiotherapy, radioisotope treatment, cytotoxic chemotherapy and hormone therapy. He is also the Clinical Lead for the All Wales Prostate Cancer Brachytherapy service based at Velindre Cancer Centre. 

Dr Lester is a member of Royal College of Physicians, Fellow of the Royal College of Radiologists, Honorary Research Fellow, Cardiff School of Medicine and British Thoracic Oncology Group Committee Member. He also manages The Stepping Stones Appeal, the Wales-based lung cancer research fund.

Dr Charlotte Rees is a Consultant Medical Oncologist based at University Hospital Southampton, where she is the lead for chemotherapy.

Charlotte completed specialist training in medical oncology at The Royal Marsden Hospital between 1996 and 2003. She was also actively involved in the recruitment of patients to phase I to III clinical trials throughout her training and while working for the Institute of Cancer Research at Sutton she was involved in the phase I trials unit.

Dr Rees worked as a consultant in medical oncology and was honorary lecturer at St George’s Hospital, Tooting, London, from 2003 to 2005.

Dr Rees sits on the National Specialist Advisory Committee for Medical Oncology. She is the training programme director for medical oncology for the Wessex deanery and has a Medical Research Council scholarship for BSc in pharmacology. 

Dr Rees is a member of network chemotherapy group and a member of network upper gastrointestinal cancers network group.

Dr Andrew Hindley is a Consultant Clinical Oncologist based at The Cancer Centre at Royal Preston Hospital.

Dr Hindley qualified at Birmingham University Medical School in 1977, having been on a travelling scholarship to Malaysia. His elective was spent in oncology at the University of Heidelberg. After training in General Medicine he worked at the Christie Hospital in Clinical Pharmacology, learning how to use anti-cancer drugs, safely and effectively, and carried out research into hormone therapy of breast cancer. He then underwent training in radiotherapy and first became a Consultant in New Zealand prior to taking up his current consultant appointment at Royal Preston Hospital in 1997. 

His clinical interests are in breast cancer, lung cancer, gynaecological, central nervous system and skin cancer. He is actively involved in research into new treatments and training medical students and junior doctors.

His publications have covered hormone therapy and breast cancer, radiotherapy for gynaecological cancer and head and neck cancer, and chemotherapy for gynaecological cancer. His clinical interests are in breast cancer, lung cancer, gynaecological, central nervous system and skin cancer.

In addition to his clinical role Dr Hindley is the Network Clinical Lead for Research and is committed to improving cancer treatment and supportive care for patients in clinical trials. His particular research interests include chemotherapy for platinum resistant disease in ovarian cancer, overcoming unwanted effects of radiotherapy and development of new treatments for brain tumours.

Dr Lip Lee is a Consultant Clinical Oncologist based at The Christie NHS Foundation Trust in Manchester.

Dr Lee graduated from University of Melbourne, Australia in 1997. From there he started his general medical training in the UK. 

He started working in oncology in the Christie, Manchester in 2000, after completing his MRCP. During the course of his training in oncology at the Christie, he also visited the MD Anderson cancer centre and William Beaumont Hospital in the USA to develop further specific technical skills in IMRT and SABR. 

He is one of the clinical leads who developed stereotactic lung radiotherapy for lung cancer for the first time in the North West and is constantly involved with new developments in IMRT for head & neck and lung cancers.

Dr Lee was on the examination panel for Royal College of Radiologists, UK and Manchester medical school, and is currently the ‘Training Programme Director’ for the oncology training in the North West Region.

He speaks numberous anguages including English, Cantonese, Mandarin, Hakka, and Indonesian.

Dr Fiona Blackhall is a Consultant Medical Oncologist based at The Christie Foundation NHS Trust in Manchester.

She is Lung Cancer Research Group Lead at Manchester Cancer Research Centre and the Lung Disease Group Chair at The Christie.

Dr Blackhall was a undergraduate at St Andrews and Manchester Universities.  She undertook an intercalated BSc in St Andrews in the laboratory of Dr Peter Bryant in the field of radiobiology and DNA repair, and commenced Medical Oncology training at The Christie Hospital in 1995.

Dr Blackhall's overall objective is to contribute clinically relevant lung cancer research to improve outcomes for lung cancer patients and ultimately to make lung cancer a less common and less deadly disease. 

Dr Fiona Blackhall holds Memberships of Committees and Professional Bodies on:

The British Thoracic Oncology Group; European Thoracic Oncology Platform; European Society of Medical Oncology (Faculty Member); American Society of Clinical Oncology (Faculty Member; Advanced Disease Subgroup member, NCRI Lung Clinical Studies Group; and The International Association for the Study of Lung Cancer (Faculty Member)

Dr Shan Chetiyawardana is a Consultant Clinical Oncologist based at Queen Elizabeth Hospital in Birmingham.

Dr Chetiyawardana has been in post as a Consultant Oncologist at the Queen Elizabeth since 1983, providing oncology services including radiotherapy, chemotherapy, hormone therapy and targeted therapy for breast, lung and urological tumours at Walsall Manor and Queens Hospital, Burton. He conducts seven clinics and attend 6 MDT per week. 

Dr Chetiyawardana is the service lead for Radiotherapy and Chairman of the Oncology Executive Committee at University Hospital Birmingham. He is also the Honorary Senior lecturer at Birmingham University, and a member of the MAC at Spire Little Aston Hospital and lead clinician for Cancer at Spire Little Aston.

Dr Chetiyawardana is a member of Royal College of Radiologists and the International Association for Lung Cancer.

Dr Richard Griffiths is a Consultant Medical Oncologist based at The Clatterbridge Cancer Centre in The Wirral.  He is also an Honorary Clinical Lecturer at The University of Liverpool.

Dr Griffiths graduated from The University of Liverpool in 1998 and trained in Medical Oncology at The Christie in Manchester. His PhD thesis at The University of Manchester was on immunotherapy for kidney cancer.  In 2010 he Joined The Clatterbridge Cancer Centre where he maintains an active research interest. 

As a medical oncologist, Dr Griffiths specialises in drug treatments for cancer. His areas of interest are kidney, lung and 'unknown primary' cancers. Dr Griffiths has an interest in clinical research and is the principle investigator on a number of phase II and III clinical trials at Clatterbridge. 

Mr Rajesh Shah is a Consultant Thoracic Surgeon based at Universtiy Hospital South Manchester NHS Foundation Trust.

Mr Shah is specialty lead in thoracic surgery at UHSM and he trained in Bombay, following on to the UK where he underwent post graduate training in cardiothoracic surgery in Birmingham, Edinburgh and Yorkshire. In 2003 he was appointed as a consultant thoracic surgeon at UHSM and more recently has been the clinical lead for thoracic surgery.

Mr Shah is the programme director & chair of the North West Cardiothoracic Training Committee and he is an examiner of MRCS / FRCS (C/Th). Mr Shah is also the trustee of the SCTS executive committee and part of the faulty standard setting committee intercollegiate board. Mr Shah is also an elected representative and the education secretary for the Society for Cardiothoracic Surgery of GB and Ireland.